Who We Are
Founded in 2013, POL Scientific, LLC is an open access publisher specializing in the publication of basic research and medical journals covering a diverse spectrum of life sciences and medicine for the benefit of humanity. Our leading journals include: 1) Journal of Biological Methods (ISSN: 2326-9901), committed to publish innovative biological protocols and techniques; 2) Bladder (ISSN: 2327-2120), a medical journal dedicated to publishing research on bladder biology and disease. 3) Health Psychology Research (ISSN: 2420-8124), committed to publishing original psychology research related to health, behavioural medicine, health-related quality of life, and illness. 4) Surgical Technology International (ISSN: 1090-3941), committed to publishing original research and advances in surgical techniques, innovations, and clinical practice across all fields of surgery.
Editorial Director
Chaohong Yu
Tongji Medical College of HUST
Prof. Chaohong Yu graduated from Tongji Medical College of Huazhong University of Science and Technology (HUST) in 1983 and began his career as an editor for the bulletin of Tongji Medical College (published in English). Awarded a WHO scholarship in 1989, he pursued postgraduate studies in the U.S. and later earned a Master’s in Library and Information Science in 2020. He was promoted to Associate Professor in 1996. With extensive expertise in translating, writing, and polishing scientific papers, Prof. Yu teaches a graduate course on scientific writing at Tongji Medical College of HUST. He previously served as a highly-renowned English training instructor in Wuhan. He worked as the head of the Journal Department of Tongji Medical College of HUST for over ten years and the Executive Editor of the Current Medical Science (published English) for over 30 years. He served as a senior English editor of Arthroplasty, and is currently a Senior Editor of Bladder and and Journal of Biological Methods.
Publisher
Weimin Ci, Ph.D.
Chinese PLA General Hospital
Prof. Weimin Ci is currently a Professor in the Department of Urology at the Chinese PLA General Hospital, focusing on precision medicine for genitourinary cancers. She earned her B.S. in Physics from Beijing Normal University in 1999 and her Ph.D. in Biophysics from the Institute of Biophysics, Chinese Academy of Sciences, in 2004, where she investigated iron uptake signaling pathways in human K562 cells. She continued her research in the United States as a Research Associate at Albert Einstein College of Medicine (2004–2008), studying transcriptional regulation in B-cell lymphomas, followed by a Postdoctoral Associate position at Weill Cornell Medical College (2008–2009). Returning to China, Prof. Ci joined the Beijing Institute of Genomics, Chinese Academy of Sciences, serving as Associate Professor (2009–2014) and later Professor (2014–2024), with research interests spanning cancer genomics, cancer stem cells, cancer epigenetics, and precision medicine. Her multidisciplinary expertise integrates biophysics, molecular biology, and genomics to advance cancer research and therapeutic strategies.
Xi Wang, PhD
Capital Medical University
Dr. Xi Wang is serving as Professor and Executive Dean of the Beijing Institute of Infectious Diseases, Director of the Beijing Ditan Hospital Research Center, and Vice Chair of the Department of Oncology at Capital Medical University. He completed his medical training (BM) and Master's in Basic Medicine at Peking University, earned his PhD in Cellular and Developmental Biology from Pennsylvania State University, USA, and conducted postdoctoral research at Harvard University Medical School. With a robust background in molecular and clinical sciences, Dr. Wang's research is deeply engaged in the field of epigenetics in cancer immunotherapy, exploring novel mechanisms to enhance therapeutic efficacy. He has contributed significantly to academia through numerous high-impact publications and holds key editorial roles, including Executive Editor of the Journal of Biological Methods and Editorial Board Member for Cancer Biology & Medicine and Aging Medicine. Additionally, he provides strategic leadership as the Chair of the Committee of Infectious Diseases at the Beijing Society for Chronic Illness
Publishing Consultant
Xu Zhang, M.D., Ph.D.
Academician-Chinese Academy of Science
Prof. Xu Zhang is the director and professor of urology at the Chinese PLA General Hospital in Beijing, China. He is the Chairman designate of Chinese Urological Association. He has long committed to promote the development of minimally invasive urology in China. He has personally performed over 10,000 cases of laparoscopic procedures and over 5000 cases of robotic procedures, established and promoted retroperitoneal laparoscopic surgeries, and pioneered in many new techniques of robotic procedures such as robotic IVC thrombectomy, robotic kidney transplantation, robotic prostatectomy and robotic partial nephrectomy. He had been invited to perform live surgery at many international conferences for the last 20 consecutive years and trained more than 1300 urological laparoscopic specialists at home and abroad.
Yongfeng Shang, PhD
Academician - Chinese Academy of Sciences
Prof. Shang is the Professor of Biochemistry and Molecular Biology at Peking University Health Science Center, China. He is an accomplished Molecular Biologist whose research focuses on the molecular mechanisms driving breast and endometrial cancers. He obtained his Ph.D. from Pennsylvania State University and conducted postdoctoral research in the laboratory of Dr. Myles Brown at the Dana-Farber Cancer Institute, Harvard Medical School. In 2002, he returned to China to establish his research program at Peking University. Dr. Shang's work has led to significant insights into estrogen signaling, epigenetic regulation in metastasis, and novel tumorigenesis genes, published in leading international journals. His scientific excellence was recognized with his election as an Academician of the Chinese Academy of Sciences in 2009. Complementing his research, Dr. Shang has served in key leadership roles, including as President of Tianjin Medical University and Capital Medical University, and contributes to the scientific community through editorial board service.
Xingjie Liang, Ph.D.
National Center for Nanoscience and Technology, Beijing, China
Dr. Xingjie Liang earned his Ph.D. from the National Key Laboratory of Biomacromolecules at the Institute of Biophysics, Chinese Academy of Sciences (CAS). He subsequently completed five years of postdoctoral training in the laboratory of Dr. Michael M. Gottesman at the National Cancer Institute, NIH, followed by a Research Fellow position at the Surgical Neurology Branch, NINDS, NIH. He is currently a Principal Investigator at the Center for Excellence in Nanoscience, CAS. Dr. Liang serves as the President of the Chinese Association of Nanobiology and is an elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE). He has led the development of an "Injectable Nanomicelle Powder with Irinotecan," which has received CFDA approval and advanced to clinical trials. His research focuses on leveraging nanotechnology to enhance drug bioavailability and therapeutic efficacy against cancers and infectious diseases, with a current program aimed at overcoming clinical adaptive treatment tolerance.
Benyi Li, M.D., PhD
The University of Kansas Medical Center
Professor Benyi Li received his medical training in China and completed his Ph.D. work in Japan. He moved to the United States in 1998 and transitioned to urological research. After completing two postdoctoral fellowships at Moffitt Cancer Center and Baylor College of Medicine, he joined the faculty of the University of Kansas Medical Center's Urology department at the end of 2001 and established the department's basic research program. His research focuses on prostate cancer, with a focus on developing innovative clinical therapies for patients with advanced prostate cancer. His laboratory is dedicated to uncovering the molecular mechanisms of cancer development and developing novel therapeutic strategies based on these insights.
Managing Editor
Li Yang (Eleanore), Master
Eleanore Yang, with a master's degree in Environmental Science and Engineering, is responsible for overseeing operations and editorial management. With eight years of extensive experience in the publishing industry, she has exceptional skills in managing journals. The adherence to quality control motivates her continuous exploration and drives her ever forward
Yuqian Zhao (Daisy), Master
Daisy oversees operations and editorial management. With four years of experience in the publishing industry, she is committed to upholding the highest standards of quality and integrity. The goal is to position each journal as a leader in its field while fostering a culture of innovation and continuous improvement.